Loading…
Chinese OTC and traditional-Chinese-medicine drugmaker owned by state conglomerate China Resources.
Chinese OTC and traditional-Chinese-medicine drugmaker owned by state conglomerate China Resources.
Sells over-the-counter remedies, mainly cold, stomach and skin products under its 999 brand, through pharmacy chains and wholesalers, so branding and pharmacy shelf presence matter more than doctor prescriptions. China Resources Group's drug-distribution network gives it reach across China. Traditional Chinese medicine granules and prescription drugs are smaller lines.
In one line: A Chinese Bayer Consumer Health for OTC/TCM brands.
Moat: narrow (brand, distribution, scale). Well-known consumer OTC brands and a nationwide pharmacy distribution network under China Resources.
Headquarters: Shenzhen, China · Founded: 1985 · Employees: 30,304
Size China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $6.48B, the 380th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥25.95 on 6 Nov 2026.
Performance Over six months the shares gained 0.1%, against -1.3% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue grew 4.2% over the last twelve months (peer median +6.0%); the operating margin is 13.7% (peer median 16.5%).
Valuation It trades at 12.8× forward earnings against a peer median of 25.7× (2nd cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -25 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥31.0B | CN¥31.4B | CN¥27.4B | CN¥24.5B | CN¥17.9B |
| Revenue growth | — | +14% | +12% | +37% | — |
| Gross profit | CN¥18.0B | CN¥16.1B | CN¥13.8B | CN¥12.7B | CN¥9.45B |
| EBITDA | n/a | CN¥5.82B | CN¥5.11B | CN¥4.38B | CN¥3.35B |
| Net income | CN¥3.23B | CN¥3.42B | CN¥3.37B | CN¥2.85B | CN¥2.45B |
| Free cash flow | CN¥3.69B | CN¥4.34B | CN¥3.69B | CN¥3.36B | CN¥2.12B |
| Capital expenditure | CN¥1.40B | CN¥1.27B | CN¥790M | CN¥857M | CN¥952M |
| Total debt | CN¥4.94B | CN¥7.31B | CN¥2.26B | CN¥3.94B | CN¥909M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% |
| Beijing TongRenTang 600085.SS | $5.27B | -8% | -17% | 8% | 31.2× | 2.7% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% |
| Bayer BAYN.DE | $61.2B | +46% | -2% | 14% | 12.3× | 2.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000999.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.0% | +1.9% | 6th highest of 21 |
| 6-month return | +0.1% | -1.3% | 9th highest of 20 |
| Distance from 52-week high | -15.3% | -14.1% | 10th lowest of 21 |
| Revenue growth (TTM) | +4.2% | +6.0% | 6th lowest of 17 |
| Operating margin | 13.7% | 16.5% | 7th lowest of 18 |
| Forward P/E | 12.8× | 25.7× | 2nd cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -6.3% | 6.4% | 3rd least demanding of 11 |
| Growth delivered (Del g) | +18.4% | +10.3% | 4th highest of 11 |
| Hurdle (Req g minus delivered) | -24.7 pp | -12.9 pp | 4th least demanding of 11 |
| ROIC minus cost of capital | +4.4 pp | +1.7 pp | 8th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% | +18.4% |
| Ionis Pharmaceuticals IONS | United States | $6.55B | -48% | -7% | -68% | n/a | n/a | n/a |
| Gan & Lee Pharmaceuticals 603087.SS | China | $6.40B | +21% | +14% | 20% | 29.7× | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.39B | -36% | n/a | -25% | 24.0× | n/a | n/a |
| Alkem Laboratories ALKEM.NS | India | $6.67B | -5% | +13% | 17% | 27.4× | 24.3% | +10.7% |
| Biocon BIOCON.NS | India | $6.28B | -4% | +6% | 8% | 56.4× | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.20B | 0% | n/a | n/a | n/a | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |
| Ligand Pharmaceuticals LGND | United States | $6.12B | +38% | +1% | 14% | 28.0× | 57.8% | +7.5% |
| Mirum Pharmaceuticals MIRM | United States | $6.12B | -13% | +42% | -21% | n/a | n/a | n/a |
| RemeGen 688331.SS | China | $6.90B | -26% | +272% | 61% | 11.9× | 2.8% | +303.3% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 14.7× | -8.2% | +10.8% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% | +8.7% |
| Abbott India ABBOTINDIA.NS | India | $5.93B | -1% | +6% | 28% | 32.4× | 11.4% | +10.0% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.90B | -6% | +39% | 47% | 13.8× | 1.8% | +519.6% |
| Veradermics MANE | United States | $5.80B | +31% | n/a | n/a | n/a | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% | +5.3% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 33.1× | n/a | n/a |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% | +45.5% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | n/a | n/a | n/a |
| Apotex Health APTX.TO | Canada | $5.62B | n/a | +4% | 32% | 18.6× | -13.5% | +4.2% |